Harvard Apparatus Regenerative Technology, Inc. (NASDAQ: HART), a
clinical stage biotechnology company developing regenerated organs for
transplant, initially focused on the trachea, today announced that it is
proposing to offer shares of its common stock and Series B Convertible
Preferred Stock (“Series B”) in an underwritten public offering.
for Harvard Apparatus Regenerative Technology, Inc. Announces Proposed Public Offering of Common Stock and Series B Convertible Preferred Stock investment picks